

## Literaturverzeichnis

Hamburger Ärzteblatt 07/08 | 2020

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 12 – 16: Drip-and-drive-Modell: Neue Versorgungsmodelle in der akuten Schlaganfalltherapie.

*Von Dr. Caspar Brekenfeld, PD Dr. Einar Goebell, Prof. Dr. Götz Thomalla, Prof. Dr. Christian Gerloff, Prof. Dr. Jens Fiehler*

1. Berkhemer OA, Fransen PS, Beumer D, Van Den Berg LA, Lingsma HF, Yoo AJ et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* 2015;372:11-20.
2. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* 2015;372:1019-1030.
3. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med.* 2015;372: 2285-2295.
4. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* 2015;372:1009-1018.
5. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* 2015;372: 2296-2306.
6. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. *Cochrane Database of Systematic Reviews* 2013, Issue 9. Art. No.: CD000197. DOI: 10.1002/14651858CD000197.pub3.
7. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med.* 1995;333:1581-1587.
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med.* 2008;359:1317-1329.
9. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med.* 2018;378:11-21.
10. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S et al. DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *N Engl J Med.* 2018;378:708-718.
11. Sheth SA, Jahan R, Gralla J, Pereira VM, Nogueira RG, Levy EI et al. Time to endovascular reperfusion and degree of disability in acute stroke. *Ann Neurol.* 2015;78:584-593.
12. Goyal M, Jadhav AP, Bonafe A, Diener H, Mendes Pereira V, Levy E et al. Analysis of Workflow and Time to Treatment and the Effects on Outcome in Endovascular Treatment of Acute Ischemic Stroke: Results from the SWIFT PRIME Randomized Controlled Trial. *Radiology.* 2016;279:888-897.
13. Menon BK, Sajobi TT, Zhang Y, Rempel JL, Shuaib A, Thornton J et al. Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) Randomized, Controlled Trial. *Circulation.* 2016;133:2279-2286.
14. Pfaff J, Pham M, Herweh C, Wolf M, Ringleb PA, Schönenberger S et al. Clinical outcome after mechanical thrombectomy in non-elderly patients with acute ischemic stroke in the anterior circulation: primary admission versus patients referred from remote hospitals. *Clinical neuroradiology.* 2015;27:185-192.
15. Weber R, Reimann G, Weimar C, Winkler A, Berger, K, Nordmeyer H et al. Outcome and periprocedural time management in referred versus directly admitted stroke patients treated with thrombectomy. *Therapeutic advances in neurological disorders.* 2016;9:79-84.
16. Mohamad NF, Hastrup S, Rasmussen M, Andersen MS, Johnsen SP, Andersen et al. Bypassing primary stroke centre reduces delay and improves outcomes for patients with large vessel occlusion. *Eur Stroke J.* 2016;1:85-92.

## Literaturverzeichnis

Hamburger Ärzteblatt 07/08 | 2020

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekhh.de](mailto:verlag@aekhh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

17. Froehler MT, Saver JL, Zaidat OO, Jahan R, Aziz-Sultan MA, Klucznik RP et al. STRATIS Investigators. Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke). *Circulation*. 2017;136:2311-2321.
18. Fiehler J, Cognard C, Gallitelli M, Jansen O, Kobayashi A, Mattle HP et al. European recommendations on organisation of interventional care in acute stroke (EROICAS). *International Journal of Stroke*. 2016;11:701-716.
19. Brekenfeld C, Goebell E, Schmidt H, Henningsen H, Kraemer C, Tebben J et al. 'Drip-and-drive': shipping the neurointerventionalist to provide mechanical thrombectomy in primary stroke centers. *J Neurointerv Surg*. 2018;10:932-936.
20. Seker F, Möhlenbruch MA, Nagel S, Ulfert C, Schönenberger S, Pfaff J et al. Clinical results of a new concept of neurothrombectomy coverage at a remote hospital-"drive the doctor". *Int J Stroke*. 2018;13:696-699.
21. Wei D, Oxley TJ, Nystal DA, Mascitelli JR, Wilson N, Stein L et al. Mobile Interventional Stroke Teams Lead to Faster Treatment Times for Thrombectomy in Large Vessel Occlusion. *Stroke*. 2017;48:3295-3300.
22. Alegiani AC, Dorn F, Herzberg M, Wollenweber FA, Kellert L, Siebert E et al. Systematic evaluation of stroke thrombectomy in clinical practice: The German Stroke Registry Endovascular Treatment. *Int J Stroke*. 2019;14:372-380.
23. Seker F, Fiehler J, Möhlenbruch MA, Heimann F, Flottmann F, Ringleb PA et al. Time Metrics to Endovascular Thrombectomy in 3 Triage Concepts: A Prospective, Observational Study (NEUROSQUAD). *Stroke*. 2020;51:335-337.

### S. 28 – 29: Neuerungen beim Zervixkarzinom-Screening.

Von PD Dr. Lutz Riethdorf, PD Dr. Volkmar Küppers

1. Marquardt K, Stubbe M, Broschewitz U. Zervixkarzinome in Mecklenburg-Vorpommern. *Pathologe* 2016;37:78–83.
2. [www.kbv.de](http://www.kbv.de); [www.kbv.de/html/43282.php](http://www.kbv.de/html/43282.php).
3. Krebs in Deutschland für 2015/2016. 12. Ausgabe. Robert Koch-Institut (Hrsg.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg.). Berlin, 2019

### S. 30 – 31: Fulminante Nebenwirkungen von Checkpoint-Inhibitoren.

Von Tim Salzbrunn, Dr. Robert Berger, Prof. Dr. Joachim Röther

1. Callahan MK, Postow MA & Wolchok JD. Targeting T cell co-receptors for cancer therapy. *Immunity* 44, 1069–1078 (2016).
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol*. 2008;26:677–704.
3. Research, Center for Drug Evaluation and. „Approved Drugs - FDA grants regular approval to nivolumab for adjuvant treatment of melanoma". [www.fda.gov](http://www.fda.gov). Retrieved 2018-04-12.
4. Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. *Curr Opin Oncol*, 2017;29:136–144.
5. Knauss S, Ginesta Roque L, Hühnchen P, Heinzerling L, Böhmerle W, Endres M. Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. *Nervenarzt* 2019. 2018;90:138-147.
6. Touat M et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. *Neurology*® 2018;91:e985-e994. doi:10.1212/WNL.00000000000006124.

## Literaturverzeichnis

Hamburger Ärzteblatt 07/08 | 2020

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

7. Touat M, Maisonobe T, Knauss S et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. *Neurology* 2018;91:e985–e994.
8. Boland P1, Heath J, Sandigursky S. Immune checkpoint inhibitors and vasculitis. *Curr Opin Rheumatol.* 2020 Jan;32(1):53-56. doi: 10.1097/BOR.0000000000000672.
9. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. *Am J Clin Oncol.* 2016;39:98–106.
10. Manson G, Norwood J, Marabelle A et al. Biomarkers associated with checkpoint inhibitors. *Ann Oncol* 2016;27:1199–1206.

### S. 32 – 33: Die drastischen Folgen einer psychischen Störung.

*Von Rüdiger Kurz, Prof. Dr. Klaus Püschel, Dr. scient. pth Nassim Agdari-Moghadam, PD Dr. Jakob Matschke, Dr. Frauke Ishorst-Witte*

1. Falkai P, Wittchen H-U (Hrsg.). American Psychiatric Association (APA) 2015. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5. Dt Ausgabe Göttingen: Hogrefe.
2. Külz AK, Vorderholter U. Pathologischer Horten. Göttingen: Hogrefe 2018.
3. Agdari-Moghadam N. Pathologisches Horten. Berlin: Springer; 2018.
4. Walter M, Bilke-Hensch O. Narzissmus Grundlagen-Formen-Interventionen. Stuttgart: Kohlhammer 2020.
5. Pollmächer T. Zur Legitimität fremdnützigem Handeln in der Medizin und speziell in der Psychiatrie. *Forens Psychiatr. Psychol Kriminol* 2019;13:412.

### S. 36 – 37: Die Pionierin für Frauen in der Medizin.

*Von Prof. Dr. Oswald Müller-Plathe*

1. Böhm H. Dorothea Christiane Erxleben. Ihr Leben und Wirken. Städt. Museen Quedlinburg, 1985.
2. Schmiedgen U. Dorothea Christiana Leporin, verheiratete Erxleben. Pfarrfrau und streitbare Ärztin in Quedlinburg. In: Brinkschulte E, Labouvie E (Hrsg.). Dorothea Christiana Erxleben. Weibliche Gelehrsamkeit und medizinische Profession seit dem 18. Jahrhundert. Mitteldeutscher Verlag, Halle, 2006.
3. Bleker J. Das Ende des männlichen Berufsmonopols in Deutschland. In: Schott H : Meilensteine der Medizin. Harenberg 1996.
4. Wikipedia: Frauenstudium im deutschen Sprachraum. (Zuletzt bearbeitet 11.2.2020)
5. Müller-Plathe O. Aus der Geschichte des Altonaer Krankenhauses. Husum Verlag 2011.